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INTRODUCTION 
 
Myopia or shortsightedness is defined as a type of refractive error in which 
parallel rays of light coming from infinity are focused in front of retina when 
accommodation is at rest 
 
Myopia is divided into the following types, namely1 
 
 
· mild myopia:          -1D to -3D; 
 
· moderate myopia:   -3D to -6D; 
 
· high myopia:           -6D to -12D; 
 
· extreme myopia       >12D. 
 
 
Myopia could be simple myopia ( axial, curvatural and index) or pathological 
myopia, which is characterized by increased axial length and degenerative changes in the 
eye.  
 
Myopia can be corrected by non-surgical and surgical means. Modalities of non-
surgical correction include the use of spectacles with a concave lens, and the wearing of 
contact lenses 
 
Several modalities have been used for the surgical correction of myopia, namely: 
 
 
      (1) radial keratotomy (RK), which is now only of  historical importance;  
 
 
(2) photo -refractive keratotomy(PRK); 
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(3) laser- in- situ keratomileusis (LASIK);  
 
 
(4) intrastromal corneal ring segments/ Intacs (ICSR); 
 
 
                  (5) clear lens extraction or refractive lens exchange;  
 
 
(6) implantable collamer lens (ICL) or phakic intraocular lenses (pIOLs). 
 
 
 
The implantable collamer lens (ICL) represents a new category of IOLs that 
expands the range of keratorefractive surgery. This device allows patients with large 
refractive errors (myopia, hypermetropia) to achieve predictable outcomes, especially in 
those patients in  whom laser refractive surgery is limited by the amount of corneal tissue 
that can be ablated and/or by the predictability of results. 
 
  Phakic IOLs are available as both foldable and non-foldable lenses and can be 
placed in the anterior or posterior chamber .Anterior chamber lenses are further divided 
into Angle supported or Iris clawed IOLs 
 
The use of  Phakic IOLs began in the 1950s in Europe with Strampelli2, 
Dannheim3, Barraquer4 each separately attempting to design a better IOL Lack of modern 
IOL manufacturing capability and lack of microsurgical techniques resulted in a high 
incidence of complications such as corneal oedema, iritis, cataract and glaucoma.  
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             In 1986-88, Baikoff presented his version of an anterior chamber angle fixated 
IOL5. The Baikoff ZB (Domilens,Lyon,France) was the first model to be distributed 
worldwide in 1986. This was replaced by ZB5M and ZB5MF lenses. In 1990s NuVita 
MA20 lens (Bausch And Lomb) was introduced. The Baikoff IOL is a single piece, 
biconcave anterior chamber lens based on Multiflex Kelman anterior chamber IOL. It is 
made of polymethylmethacrylate (PMMA) containing an ultraviolet blocker. The Kelman 
Duet (Tekia) is an angle-supported lens with independent PMMA haptics and frame, and 
a third-generation silicone optic. This lens comes in two separate pieces that are 
assembled inside the eye, and it has several advantages. The haptic can be  exchanged 
leaving in the optic in the eye and vice versa. 
                                                                                                                                               
  Recently Alcon (Fortworth,TX,USA) introduced the Acrysof lens, a foldable 
single piece IOL made of soft acrylic. The complications of angle supported phakic lens 
included pupillary block, endothelial cell loss, haloes and glare, iritis, implant rotation 
and iris retraction with irregular pupil formation. 
 
 
Iris supported phakic lenses, Artisan, were developed by Ophtec BV 
(Groninngen, Netherland) in 1991 and brought to USA as Verisyse phakic IOLs after US 
FDA approval in 2004. The Verisyse lens is a single piece lens made from PMMA with 
ultraviolet light absorbing material. It has a concave-convex optic incorporated into an  
8.5mm elliptical plate lens and a slight anterior vault that creates space for aqueous flow 
and avoids contact with the crystalline lens. Artiflex is a flexible version of the Artisan  
“iris claw” lens, which has a special injector that allows it to be implanted through a  
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3.2mm incision. Like the Artisan, the iris claw haptics of the Artiflex are made from 
PMMA. The greatest risk of foldable anterior chamber lenses is the unfolding movement. 
The Artiflex lens is introduced into the anterior chamber with the specially designed 
spatula through a small incision The withdrawal of the spatula automatically releases the 
IOL and allows it to unfold in the eye. The IOL is moved to center of the pupil and 
enclaved. Like Artisan, Artiflex also has the advantage of one size- fits- all. The toric 
version of Artisan and Artiflex need additional care and accuracy during implantation. 
The need continues to exist for a safe bio-compatible and easily fixated anterior chamber 
IOLs. 
 
There are currently four models, 203 for correction of hyperopia, 204 and 206 for 
correction of myopia and toric model for correction of astigmatism 6mm. Of these only  
two models have been approved by FDA. The model 204 corrects myopia of -5D to -15D 
with optical zone of 6mm, model 206 corrects myopia of -5D to -20D with optical zone 
of 5mm.  
 
                Like angle supported phakic lenses, iris supported lenses too have similar risks 
after implantation like decreased endothelial cell count, elevation of intraocular pressure 
and chronic subclinical intraocular inflammation 
 
The challenge in refractive surgery is presbyopia, which affects most people older 
than 40 years. The Bifocal refractive Phakic IOL (pIOL) is an anterior chamber angle 
supported lens marketed under the name of Newlife (IOL Tech) and Vivarte 
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(Cibavision). The optic is soft 28% hydrophilic acrylic and the haptic is PMMA and 
footplates are hydrophilic acrylic. The 5.5mm diameter optic is divided into center 
1.50mm for distance, the intermediate 0.55mm for near and periphery 1.45mm for 
distance vision. The overall size of the lens varies from 12mm to 13mm.The IOL power 
ranges from –5D to +5D with +2.5D addition for near vision. 
 
Posterior chamber IOLs have evolved in the past decade, and problems such as 
the risk of secondary cataract have been minimized. The Staar Surgical ICL is made of a 
collagen copolymer, a compound combining acrylic and porcine collagen (<0.1% 
collagen). It’s  refractive index is 1.45 at 35º C. The material is soft, elastic, and 
hydrophilic. The Visian ICL (STAAR Surgical) has reduced the risk of secondary 
cataract to 1%. Phakic ICL for myopia correction is available from –3 D to –23 D, optical 
diameter 5.50mm.  
 
 Phakic ICL for hyperopia correction is available from +3.0D to +21.5D, optical 
diameter 5.50mm. Toric ICL for myopia correction is available from -3.0D to -23D, 
Cylindrical power in half diopter increments from +1.0D to +6.0D 
 
Implantation of posterior chamber IOLs in phakic eyes was reported by Fyodorov 
et al (1987). The original lens design was collar button type, with the optic located in the 
anterior chamber and the haptic behind the iris plane. 
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             Later, Chiron-Adatomed modified this design to produce a silicon elastomer 
posterior chamber lens6.This lens design has been reported to have a high incidence of 
cataract formation after implantation  
 
             In 1993, Zaldivar et al began implanting a plate posterior chamber phakic IOL 
(Staar surgical implantable contact lens) (Zaldivar et al 1998). This lens design was  
modified from one that Fydorov introduced in 1986-87, using a one piece silicon collar 
button phakic IOL with a 500-600 nm Teflon coat. Incorporation of a porcine collagen 2- 
Hydroxyethylmethacrylate (HEMA) copolymer into the lens material has improved the  
compatibility of this lens.  
 
These improvements in ICL manufacture and modern microsurgical technique 
with improved knowledge of corneal endothelium and anterior segment structures led to 
greater success than with the original lens 
 
              This procedure not only gives satisfactory postoperative visual acuity but also 
improves quality of vision by overcoming limitations in night vision, loss of best 
corrected visual acuity (BCVA), visual aberration and diminished quality of vision. 
Visual outcome and patient satisfaction after phakic IOL (pIOL) surgery have been 
shown to be superior to that of laser in situ keratomileusis (LASIK) or photorefractive 
keratectomy (PRK) especially in high myopes as induced higher order aberrations are 
less and refractive results are more stable postoperatively7  
Recently Phakic IOLs are available for correction of anisometropic amblyopias and 
presbyopia (bifocal lenses in anterior chamber) 
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The Food and Drug Administration of the USA (FDA) has approved 2  Phakic 
IOLs  for myopia, namely the Posterior chamber Visian (STAAR) ICL Iris supported 
phakic intraocular lens (Verisyse)  
 
Advantages of ICL implantation over other refractive procedures are excellent 
refractive accuracy, preservation of corneal asphericity (neither change in shape nor 
change in thickness) and preservation of accommodation, reversibility of the procedure 
and finally rapid visual  recovery following surgery  
 
This procedure not only gives satisfactory postoperative visual acuity but also 
improves quality of vision by overcoming limitations in night vision, loss of best 
corrected visual acuity (BCVA), visual aberration and  diminished quality of vision8  
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AIM 
 
To determine short term visual outcome and safety features following implantation of  
Implantable Collamer Lens (ICL) for correction of myopia. 
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REVIEW OF LITERATURE 
 
 
Radial Keratotomy (RK) 
 
First developed in 1898 and improved in 1960s. It is designed to correct myopia 
by making several small radial cuts on corneal surface that cause the cornea to flatten out 
in the centre .These incisions cause change in the way in which it focuses light on the 
retina. RK was most commonly used to treat patients with -1D to -4D of myopia. 
 
 Major advantages included , clear central optical zone of  3-4mm with no 
chances of  central corneal haze, this procedure was less expensive than PRK and LASIK 
and  postoperative visual recovery after this procedure was much earlier than PRK. Major 
disadvantages with this procedure were weakened cornea susceptible to rupture following 
trauma, uneven healing of cornea caused astigmatism and glare at night. One of the major 
drawbacks were also that stable, predictable results were hard to calculate. 
 
Photorefractive keratotomy (PRK) 
 
It is procedure of photoablation by Excimer laser which has been in use for  
treatment of myopia, hyperopia and astigmatism. Srinivasan, Barren and Trokel used 
Excimer laser for the first time in 1983 It gives good results from -2D to -6D of myopia 
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Indications  
 
F Superficial scars or basement membrane dystrophy with myopia 
 
F Cornea thinner than 500µ 
 
F Crowded orbits with narrow palpebral fissure 
 
F Glaucoma suspects 
 
 
 
Advantages of PRK 
 
 
F No weakening of globe unlike RK 
 
F No night glare and diurnal variation in refraction unlike RK 
 
F Results with an accuracy of 95% in achieving a ± 0.50D correction in patients 
 
            with -2D  to -6D of myopia 
 
 
Drawbacks 
 
F Corneal haze and regression 
 
F Night glare and haloes 
 
F Delayed epithelial healing 
 
F Corneal ulcer formation 
 
F Decentration of ablation zone 
 
Laser in situ keratomileusis (LASIK) 
 
It was first conceived in 1989 by Dr Pallikaris. FDA approved its use in 1999. It is 
the procedure of choice for myopia because of its definite advantages over PRK and  RK 
It can be used to correct upto -15D of myopia and upto -6D of astigmatism depending on 
the excimer laser platform used. 
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Advantages of LASIK over RK and  PRK 
 
 
· Minimal or no post operative pain 
 
· Recovery of vision is very early as compared to PRK 
 
· No or little risk of perforation during surgery and globe rupture due to trauma 
 
            unlike RK 
 
· No residual haze unlike PRK where subepithelial scarring  may occur 
 
· Can be effective in correcting  upto -15D of myopia and upto -6D of astigmatism  
 
 
 
Clear lens extraction or refractive lens exchange 
 
 
 
Clear lens exchange had been advocated for myopia of -16D to -30D, especially 
in unilateral cases even before IOLs became popular. Treatment of myopia with clear 
lens  extraction by phacoemulsification with appropriate  IOL implantation (Fucala’s 
operation) suggested that it is better to place a zero power IOL than no IOL, since it  
retards posterior capsule opacification (PCO) and reduces chances of retinal detachment 
in aphakic eyes. The minification effect of high concave glasses is removed  
 
Indications 
 
· Cornea is too thin, too flat, too steep and  alternative 
 
      refractive procedures are not feasible and 
 
· Spectacles or contact lens are unacceptable 
 
· Refractive error exceeds the limit of excimer laser  
 
      and patient is more than 45yrs old 
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 Drawbacks 
 
· Loss of accommodation 
 
· Higher chances of retinal detachment after lens extraction 
 
 
 
 Intra stromal corneal ring segments (ICRS) or Intacs Intra stromal corneal ring 
segments  can treat low amounts of myopia by displacing the lamellar bundles and 
shortening the corneal arc length. These circular rings (two arc shaped segments) are 
made of  polymethylmethacrylate (PMMA) are placed in the midperipheral corneal 
stroma in a lamellar channel. The two segments are of 150º of arc, available in five 
thicknesses (0.25,0.27,0.30,0.32 and 0.350mm) The thicker the segment, the greater the 
flattening of the cornea and the greater the reduction in myopia  
 
             There are several potential advantages of ring segments over other forms of 
refractive surgery such as reversibility of the procedure where rings can be explanted, 
rings can be replaced with ring segments of different thickness to titrate the refractive 
result, central corneal zone remains clear and aspheric because Intacs flatten the 
peripheral cornea more than the central cornea. 
 
 Certain disadvantages of intra stromal corneal ring segments make other 
refractive surgical procedures more popular. Specialized equipment and training is 
required to create the lamellar channels and to insert the ring segments, takes longer to 
perform than the  LASIK procedure, patients experience discomfort and glare after the 
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surgery and  this procedure corrects only low levels of myopia, it cannot correct 
hyperopia and   astigmatism. 
 
Complications with this procedure include anterior chamber perforation, 
microbial keratitis, implant expulsion, reduced corneal sensitivity, induced astigmatism, 
deep neovascularization at incision site  
 
Sanders et al (2004) studied 3-year postoperative safety and efficacy outcomes 
with the Myopic Implantable Collamer Lens (ICL). In this study five hundred and 
twenty-six eyes of 294 patients with spherical equivalent between -3.0 and -20.0 diopters 
(D) of myopia had participated in the United States Food and Drug Administration 
clinical trial of ICL for myopia. The main outcome measures taken for this study were 
uncorrected visual acuity (VA), refraction, best spectacle-corrected VA (BSCVA), 
adverse events, operative and postoperative complications, lens opacity analysis, 
subjective satisfaction, and patient symptoms. At 3 years, 59.3% had 20/20 or better VA, 
and 94.7% had 20/40 or better uncorrected VA if BSCVA was 20/20 and patients were 
targeted for emmetropia; 67.5% of patients were within 0.5 D and 88.2% were within 1.0 
D of predicted refraction. The mean improvement in BSCVA ranged between 0.5 and 0.6 
lines. At 3 years postoperatively, 3 eyes (0.8%) decreased by >or=2 lines of BSCVA, in 
contrast to 40 eyes (10.8%) that improved by a similar amount. Contrast sensitivity 
improved postoperatively. Cumulative 3-year corneal endothelial cell loss was under 
10%. Early largely asymptomatic, presumably surgically induced anterior subcapsular 
opacities (trace or greater) were seen in 14 eyes (2.7%), with only 2 being clinically 
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significant. Five eyes (0.9%) of 3 patients developed nuclear opacities of grade >2 at 2 to 
3 years postoperatively. Three (0.6%) ICL removals with cataract extraction and IOL 
implantation have been performed. Only 0.6% reported dissatisfaction; 97.1% of patients 
reported they would choose ICL implantation again. Incidences of patient symptoms, 
glare, halos, double vision, night vision problems, and night driving difficulties decreased 
or remained unchanged after ICL surgery. Three-year results from this standardized, 
multicenter clinical investigation support the safety, efficacy, and predictability of ICL 
surgery to treat moderate to high myopic refractive errors. 
 
 Kamiya et al (2009) assessed the long-term clinical outcomes of implantation of 
a lens consisting of a biocompatible collagen copolymer (Visian implantable Collamer 
lens [ICL]; STAAR Surgical, Nidau, Switzerland) for moderate to high myopia. They 
evaluated 56 eyes of 34 patients with myopic refractive errors of -4.00 to -15.25 diopters 
(D) who underwent ICL implantation and routine postoperative examinations. Before and 
1, 3, and 6 months and 1, 2, and 4 years after surgery, they assessed the safety, efficacy, 
predictability, stability, and adverse events of the surgery. Mean (SD) logMAR 
uncorrected and best spectacle-corrected visual acuities were -0.03 (0.23) and -0.21 
(0.09), respectively, at 4 years after surgery. The mean (SD) safety and efficacy indexes 
were 1.19 (0.25) and 0.83 (0.29), respectively. At 4 years, 44 (79%) and 52 (93%) of the 
eyes were within 0.5 and 1.0 D, respectively, of the targeted correction. Mean (SD) 
manifest refraction changes of -0.24 (0.57) D occurred from 1 month to 4 years after 
surgery. No vision-threatening complications occurred during the observation period. 
Implantation of ICLs is safe and effective and provides predictable and stable refractive 
 15
results in the treatment of moderate to high myopia during a 4-year observation period, 
suggesting its viability as a surgical option for the treatment of such eyes. 
 
Shen  et  al (2003) evaluated the efficacy, safety and stability of posterior 
chamber phakic IOL for correction of high myopia in 39 eyes of 20 patients  with high 
myopia (between -11.75 and -25.75 diopters) had a posterior chamber PIOL (Staar ICL) 
implanted. During 6 - 48 months' follow-up, visual acuity, refraction, intraocular pressure 
(IOP), corneal reaction and space between crystal lens and intraocular lens (IOLs) were 
tested. Successful implantation was achieved in all patients. Visual acuity without 
correction greater than 0.5 was found in 34 eyes at 1 day and 3 months postoperatively. 
Thirty-five eyes maintained a low negative power of refraction (-1.42 +/- 1.32 doipters), 
which did not prevent the patients from most of their daily activities. During 3 - 48 
months' follow-up, refraction was stable and no cornea edema and glaucoma was found. 
Two eyes of one patient had corticosteroid glaucoma and another eye showed 
cataractogenesis under anterior capsular membrane. It was concluded that Posterior 
chamber PIOL implantation is predictable, safe, and effective in the correction of high 
myopia, and its indications should be carefully selected. 
 
Lackner et al (2004) studied the incidence and progression of lens opacification 
after implantation of phakic posterior chamber intraocular lenses for myopia and its 
correlation with vaulting and endothelial cell density (ECD) in Department of 
Ophthalmology, University of Vienna Medical School, Vienna, Austria. An implantable 
contact lens (ICL V4, Staar Surgical Inc.) was inserted in 76 myopic eyes. Patients were 
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prospectively followed preoperatively and at 1, 3, 6, 12, 24, and 36 months. The 
uncorrected visual acuity and best corrected visual acuity (BCVA) were determined. 
Vaulting was measured optically with a Jaeger II pachymetery, and the crystalline lens 
was examined at the slitlamp for the presence and characteristics of opacification. 
Endothelial cell morphometry was performed by specular microscopy, and the ECD was 
calculated. Eyes in which lens opacification developed were followed for at least 12 
months to determine the degree and course of visual impairment. Lens opacification 
occurred in 11 eyes (14.5%). Opacification was correlated with intraoperative trauma to 
the crystalline lens, age older than 50 years, and decreased ECD values throughout the 
observation period. Vaulting of the ICL did not correlate with the risk for lens 
opacification. After onset of lens opacification, 6 eyes (55%) had a stable BCVA within 
+/-0.5 lines and 5 eyes had progressive opacification, losing between 3.5 lines and 0.5 
lines (mean 1.8 lines +/- 1.1 [SD]). Three eyes (3.9%) in the progressive group had a 1- 
to 2-line loss of BCVA over preoperative values and subsequently had cataract surgery. 
Risk factors for lens opacification after implantation of the model V4 ICL included 
intraoperative trauma to the crystalline lens and older age. Decreased ECD in eyes with 
opacification suggests ongoing inflammation as a cause. Patients younger than 45 years 
may have a significantly lower incidence of opacification. 
 
Donald  Sanders  et al(2007) Compared matched populations of LASIK and 
Visian Implantable Collamer Lens (ICL) cases in the correction of myopia between -3.00 
and -7.88 diopters(D).One hundred sixty-four LASIK eyes with prospective data 
collected from a single center and 164 ICL eyes from the multicenter US ICL  
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Clinical Trial were compared in this observational non-randomized study. 
The LASIK and ICL groups were well matched for age, gender, and mean level of 
preoperative spherical equivalent refraction.At 6 months, best spectacle-corrected visual 
acuity (BSCVA) -20/20 was 85% with LASIK and 95% with ICL (P=.003) compared to  
preoperative values of 93% and 88%, respectively (P=.292). Loss of _2 lines of BSCVA 
was signifi cantly lower with the ICL at 1 week (0.6% vs 10%, P_.001) and 1 month (7% 
vs 0%, P=.001) with comparable outcomes at 6 months (0% vs 1%). At 6 months 
postoperatively, uncorrected visual acuity (UCVA) -20/15  (11% vs 25%, P=.001) and -
20/20 (49% vs 63%, P=.001) was better in the ICL cases. Predictability within 0.50 D at 
6 months for ICL cases was 85% (67% LASIK, P_.001); 97% of ICL cases were within 
1.00 D (88% LASIK, P=.002). Refractive stability (-0.50 D) between 1 and 6 months was 
93% with ICL compared to only 82%  with LASIK(P=.006). 
 
The ICL performed better than LASIK in almost all measures of safety, efficacy, 
predictability,and stability in this matched population comparison, supporting the ICL as 
an effective alternative to existing refractive laser surgical treatments for the range of 
myopia studied. 
 
Tsiklis NS et al (2007) compared the long-term results (9 years) of LASIK in one 
eye and phakic intraocular lens (implantable contact lens [ICL]) implantation in the 
fellow eye of the same patient. A patient with high myopia underwent LASIK with a 
MEL 60 excimer  laser in one eye (spherical equivalent refraction -9.75 diopters [D], 5-
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mm optical zone  with no transition zone) and phakic intraocular lens (STAAR Collamer 
implantable  contact lens [ICL]) implantation (spherical equivalent refraction -9.50 D) in 
the fellow  eye. At 9 years postoperatively, the mean spherical equivalent refraction was -
1.00 in the  eye with the ICL and -1.75 D in the eye that underwent LASIK. During the 
first 6 postoperative months in the LASIK eye, refraction regressed, but remained stable 
during  the remainder of follow-up. Uncorrected visual acuity was 20/25 in the eye with 
the ICL  and 20/30 in the LASIK eye, whereas best spectacle-corrected visual acuity was 
20/20 in  both eyes. Less night vision problems (glare and halos) were experienced in the 
eye with  the ICL compared to the LASIK eye. Although the patient initially preferred the 
LASIK  procedure, at last follow-up 9 years postoperatively, increased overall 
satisfaction was  reported for the eye with the ICL compared to the LASIK eye. Nine 
years after treatment of high myopia with the ICL and LASIK in the same patient, better 
quality of vision, stability, and satisfaction score were achieved in the eye with the ICL 
compared to the eye that had undergone LASIK. No long-term sight-threatening 
complications were found during followup. 
 
Igarashi et al(2009)  Compared postoperative visual function after implantable 
collamer  lens (ICL; STAAR Surgical, Nidau, Switzerland) implantation and after 
wavefront- guided laser in situ keratomileusis (WFG-LASIK) in eyes with high myopia.  
Retrospective, observational case study. We investigated 46 eyes of 33 patients  
undergoing ICL implantation and 47 eyes of 29 patients undergoing WFG-LASIK 
(Technolas217z; Bausch & Lomb, Rochester, New York, USA) for the correction of high 
myopia (manifest spherical equivalent < or = -6 diopters). Ocular higher-order 
 19
aberrations (HOA) and contrast sensitivity (CS) function were measured by Hartmann-
Shack aberrometry (KR-9000; Topcon, Tokyo, Japan) and a CS unit (VCTS-6500; 
Vistech Consultants Inc, Dayton, Ohio, USA) before and 3 months after surgery, 
respectively. From the CS, the area under the log CS function (AULCSF) was calculated.  
 
 For a 4-mm pupil, the changes in ocular coma-like aberrations, spherical-like 
aberrations, and total HOAs after ICL implantation were significantly less than those 
after WFG-LASIK (P < .001, Mann-Whitney U test). The postoperative AULCSF was 
significantly increased after ICL implantation (P < .001), whereas after WFG-LASIK, it 
was significantly decreased (P < .001). ICL implantation induces significantly fewer 
ocular HOAs than WFG-LASIK. Moreover, CS was improved significantly after ICL 
implantation, but deteriorated after WFG-LASIK in eyes with high myopia. Thus, in the 
correction of high myopia, ICL implantation seems to be superior in visual performance 
to WFG-LASIK, suggesting that it may be a better surgical option for the treatment of 
such eyes. 
 
ŞİMŞEK Ş et al studied to find out the refractive and visual results of posterior 
chamber lens implantation into phakic eyes for correction of high myopia and the 
reliability of the method. The Russian designed, negative silicone intraocular contact 
lenses (ICLs) were implanted into 54 eyes of 30 patients having high myopia by the same 
surgeon . 
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  Under general anaesthesia in all eyes a negative ICLs  were implanted on the 
crystalline  lens through a 6 mm corneal incision at the steepest axis and dilated pupil. A 
decrease in refractive error was achieved in all eyes. Twenty-four of the eyes (44.4 %) 
were within ±1.00 diopter (D), and all eyes were within ±2.00 D of the attempted 
correction. The mean best-corrected visual acuity (BCVA) was 4.25/10 preoperatively 
and 7.80/10 postoperatively (p<.001). No serious complication was seen except for ICL 
damage by the lens holder in 2 eyes (3.7 %) peroperatively and a transient intraocular 
pressure (IOP) increase in 9 eyes (16.6 %) in the postoperative period. The clinical and 
functional follow-up of the ICL implantation indicates that this method of high degree 
myopia correction is a good alternative when photorefractive keratectomy, LASIK and 
radial keratotomy are unavailable or unsuitable. A long term follow-up of the results of 
the  negative ICL implantation has not been made yet. Thus the clinical and functional 
results of this technique indicate the need for further improvement of this method for 
myopic correction  
 
Ahmed M Emarah et al (2010) compare the outcomes of clear lens extraction and 
collamer lens implantation in high myopia. Myopic patients younger than 40 years old  
with more than 12 diopters of myopia or who were not fit for laser-assisted in situ  
keratomileusis were included. Group 1comprised patients undergoing clear lens 
extraction and Group 2 patients received the Visian implantable collamer lens. Outcome 
and complications were evaluated. 
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Postoperative best corrected visual acuity was -0.61 ± 0.18 in Group 1 and 0.79 ± 
0.16 in Group 2. In Group 1, 71.4% achieved a postoperative uncorrected visual acuity 
better than the preoperative best corrected visual acuity, while only 51.8% patients 
achieved this in Group 2. Intraocular pressure decreased by 12.55% in Group 1, and 
increased by 15.11% in Group 2. Corneal endothelial cell density decreased by 4.47% in 
Group 1 and decreased by 5.67% in Group 2. Posterior capsule opacification occurred in 
Group 1. In Group 2, lens opacification occurred in 11.11%, significant pigment 
dispersion in 3.7%, and pupillary block glaucoma in 3.7%. 
 
Clear lens extraction presents less of a financial load up front, and less likelihood 
of the need for a secondary intervention in the future. Clear lens extraction is a more 
viable solution in developing countries with limited financial resources. 
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METHODS AND MATERIALS 
Patients with moderate to high myopia (>-3.0D to -19.0D) who underwent 
implantable collamer lens (ICL) implantation during the period from June 2009 to June 
2010 at Institute of Ophthalmology, Joseph Eye Hospital, Trichy formed the study 
population. 
 
The data collection and analysis was carried out during the period from July 2009 
to October 2010 which included 25 patients (40 eyes) who underwent implantation for 
various indications such as moderate to high myopia and compound myopic astigmatism. 
This was approved by the Institutional Ethics Committee. 
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Design 
Prospective, non randomized study 
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Main outcome measures 
Post operative visual acuity, number of eyes gaining or losing one or more lines 
(snellen visual acuity chart), predictability, efficacy index (Mean postoperative UCVA/ 
Mean preoperative BCVA), safety index (Mean postoperative BCVA/ Mean preoperative 
BCVA) and complications if any. 
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ICL Power Calculation 
 
ICL power calculation was performed by the manufacturer (Visian ICL; STAAR) 
using an online modified vertex formula on entering the necessary data i.e Refractive 
error, eye selected RE or LE for procedure, Keratometery K1 and K2 with axis, 
ACD(endothelium to lens) and White to White measurement of the cornea. Each lens is 
custom made. In all eyes, emmetropia was selected as the target refraction to reduce the 
preoperative refractive errors as much as possible 
 
Individuals were enrolled in the study if the following features were present: 
(a) Moderate to high myopia (spherical equivalent of  >-3.0D to -19.0D) 
(b) Anterior chamber depth (from corneal endothelium to lens) more than 
2.8 mm. 
(c) A round pupil with a open angle of anterior chamber  
(d) A normal  intra ocular pressure (10 mmHg- 20 mmHg) 
 
Individuals were excluded from enrollment if any of the following conditions were 
present: 
(a) inflammation of the anterior and posterior segment 
(b) chronic keratitis 
(c) corneal dystrophy 
(d) iris atrophy or rubeosis 
(e) aniridia 
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(f) cataract 
(g) vitreous pathology 
(h) retinal disease 
(i) microphthalmos 
(j) nanophthalmos 
(k) glaucoma 
(l) previous intra ocular surgery 
(m) intra ocular pressure more than 20 mmHg 
 
Each individual enrolled in the study underwent the following investigations: 
(a) accurate manifest refraction 
(b) anterior chamber depth measurement using IOL master 
(c) corneal topography 
(d) ultrasound pachymetry for measurement of central corneal thickness 
(e) white-white measurement of cornea 
(f) detailed slit lamp examination 
(g) fundus examination 
 
A standard proforma ( see Appendix) was used to collect data regarding the patients 
including name, age, sex, diagnosis, visual acuity (uncorrected and best corrected visual 
acuity both preoperatively and postoperatively) . 
 
Two weeks before the surgery,  Nd: YAG laser iridotomy were performed. On the day of 
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surgery the combination of mydriatic topical medication (e.g., tropicamide 1% with 
phenylephrine 2.5%) was applied serially, beginning 1 hour before surgery; in addition 
flurbiprofen drops were applied three times preoperatively. 
 
The anaesthesia method was based on patient and surgeon preferences and 
peribulbar anaesthesia was used for all patients in this study 
 
Surgical procedure 
An entry with MVR blade was made at the 6 o’clock position and aqueous 
humour was replaced by a viscoelastic. A temporal corneal tunnel (length- 3.2mm) was 
created using a keratome (3.2mm) and viscoelastic was injected to form the anterior 
chamber. 
 
 The implant can be inserted by one of the following two different techniques in 
which front loading injector technique was used in all patients in this study 
 
(a) With an injector as described by Arne and Hoang-Xuan (2001).Here IOL was 
positioned in the lens insertion cartridge under direct visualization with the operating 
microscope. The injector tip was placed in the tunnel and the lens is injected into the 
anterior chamber. As the IOL unfolded slowly, its progression was controlled, ensuring 
proper orientation. 
 
(b) With a forceps , the tip of which was introduced into the entrance of the tunnel. 
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Another Macpherson forceps held in the other hand to grasp the implant. The first forceps 
was opened, to regrasp the IOL a little further and to push it slowly. By repeating these 
manuvers with the forceps, the IOL was able to move in the tunnel and to unfold in a 
controlled manner. It was ensured that the tip of the forceps did not enter the anterior 
chamber to avoid contact with the crystalline lens. 
 
While the IOL was unfolding, its proper orientation was checked. Then each 
footplate was placed one after the other beneath the iris with a specially designed, flat, 
nonpolished, manipulator, without placing pressure on the crystalline lens. Care was 
taken to avoid touching the optic of the ICL in the middle, as this is the thinnest part. 
Then the OVD material was removed with gentle irrigation-aspiration and intracameral 
pilocarpine was injected. Subconjunctival injection of steroid-antibiotic was given 
Acetazolamide was given in the postoperative period to decrease the intraocular pressure. 
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ICL HELD IN CORRECT POSITION WITH STAAR 
FOAM TIP APPLICATOR 
ICL BEING LOADED IN THE INJECTOR 
CARTRIDGE 
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ICL BEING PULLED WITH FRONT LOADING  
FORCEPS INTO THE INJECTOR 
TEMPORAL CLEAR CORNEAL INCISION BEING 
MADE 
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VISCOELASTIC MATERIAL BEING INJECTED 
INTO THE ANTERIOR CHAMBER 
ICL BEING INJECTED THROUGH THE CARTRIDGE 
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ICL INITIALLY PLACED IN THE ANTERIOR 
CHAMBER 
DISTAL FOOTPLATE TUCKED BENEATH THE IRIS 
WITH VUKICH’S MANIPULATOR THROUGH 
SIDEPORT 
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PROXIMAL FOOTPLATE TUCKED BENEATH THE 
IRIS WITH VUKICH’S MANIPULATOR THROUGH 
MAIN INCISION 
 
VISCOELASTIC BEING WASHED OUT AFTER ICL 
IS PROPERLY POSITIONED IN POSTERIOR 
CHAMBER 
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RESULTS 
 
Twenty five patients were enrolled in this study , of whom 16 (64%) were females and 
nine  (36%) were males (Table-1, Figure-1).  
TABLE 1 Sex Distribution 
 
 
 
Sex Distribution Females Males 
No. of Patients 16 9 
 
 
 
 
 
FIGURE – 1 
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Age distribution 
Six (24%) patients were in the 18 -20 year age group, 12 (48%) were in the 21-25 year 
age group, five (20%) were in the 26-30 year age group and two (8%) were in the 36-40 
year age group (Table- 2, Figure -2); there was no patient in the 31-35 year age group. 
The mean age of the patients was 24.04 (±5.5) years.    
TABLE 2 - Age Distribution 
 
 
 
Age 
Distribution 
 
18-20 
Years 21-25 Years 
26-30 
Years 31-35 Years 36-40 Years 
No. of Patients 6 12 5 0 2 
 
 
FIGURE – 2 
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Laterality 
In this study,  there were 10 patients with an ICL implanted in one eye and 15 patients 
with ICLs implanted in both eyes, that is, a total of 25 patients and 40 eyes[right eye 
20(50%);left eye 20(50%)] (Table-3, Figure-3).      
TABLE 3 - Laterality 
 
 
 
Laterality Single Eye Both Eyes 
No. of Patients 10 15 
 
 
 
FIGURE – 3 
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Pre-operative refractive power                                                                                                                                                 
 
One (2.5%) of 40 eyes had a refractive power less than -5.0 D, 15 (37.5%) had a 
refractive power from -5.00 D to -10.00 D, 15 (37.5%) had a refractive power from -
10.00 D to -15.00 D, eight (20%) had a refractive power from -15.00 D to -20.00 D and 
only one (2.5%) of 40 eyes had a refractive power from -20.00 D to -25.00 D (Table-4, 
Figure -4) The mean spherical equivalent prior to surgery was -12.15 D (± 4.52D) 
TABLE 4 - Refractive power (Spherical Equivalent) 
 
 
 
Refractive 
power < -0.5D 
-5.00D to -
10.00D 
-10.00D to -
15.00D 
-15.00D to -
20.00D 
-20.00D to -
25.00D 
No. of eyes 1 (2.5%) 15 (37.5%) 15 (37.5%) 8 (20%) 1 (2.5%) 
 
 
 
FIGURE– 4 
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Type of refractive error 
 
Eight (20%) of the 40 eyes presented with simple myopia while 32 (80%) of the 40 eyes 
presented with compound myopic astigmatism (80%) (Table-5, Figure-5). Interestingly,  
the right eye was involved in seven of the eight eyes with simple myopia and only a 
single left eye had simple myopia.  
TABLE 5 - Refractive Error 
 
 
 
Refractive 
Error Simple Myopia Compound Myopic 
No. of eyes 8 32 
 
 
 
 
FIGURE – 5 
 
 
 
 
 
 39
 
 
Pre-operative best corrected visual acuity (BCVA) 
The preoperative BCVA was between 6/24 and 6/18p in one(2.5%) of the 40 eyes, 
between 6/18 and 6/12p in six(15%) of the 40 eyes, between  6/12 and 6/9p in six(15%) 
of the 40 eyes and between 6/9 and 6/6p in 17(42.5%) of the 40 eyes;  the preoperative 
BCVA was 6/6 in 10(25%) of the 40 eyes (Table-6, Figure -6).  The preoperative mean 
decimal visual acuity was 0.73(± 0.22) (approximately between 6/9 and 6/6). 
TABLE 6 - Pre Operative Best Corrected Visual Acuity(BCVA) 
 
 
Pre Operative 
(BCVA)  6/24-6/18P 6/18/-6/12p 6/12-6/9p 
6/9-
6/6p 6/6 
No. of eyes 1 6 6 17 10 
 
 
FIGURE – 6 
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Central corneal thickness(CCT) 
 
Two (5%) of the 40 eyes had a CCT from 400 to 450µ , 13(32.5%) had a CCT  from 451 
to 500µ, 18 (45%) had a CCT  from 501 to 550µ and seven (17.5%) of the 40 eyes had a 
CCT  from 551 to  600µ (Table-7, Figure-7). The mean preoperative  CCT was 511.6(± 
36.8)µ.  
TABLE 7 - Central corneal thickness in Microns 
 
 
Central corneal 
thickness in 
Microns  
Range 400-
450u 
Range 451-
500u 
Range 501-
550u 
Range 551-
600u 
No. of eyes 2 13 18 7 
 
 
FIGURE – 7 
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Anterior chamber (AC) depth 
 
The  depth of the AC was 2.8 to 3.0 mm in six(15%) of the 40 eyes, 3.01 to 3.5 mm in 
18(45%), 3.51 to 4.0 mm in 12(30%) and 4.1 to 4.5 mm in 4(10%) of the 40 eyes(Table-
8, Figure -8). The mean preoperative AC depth was 3.43(± 0.36) mm.  
 
TABLE 8 - Anterior Chamber Depth in millimeters 
 
 
 
Anterior 
Chamber depth 
in millimeters 
Range AC depth 
2.80 -3.00mm 
Range AC depth 
3.01-3.50mm, 
Range AC depth 
3.51-4.00mm, 
Range AC depth 
4.1-4.50mm, 
No. of eyes 6 18 12 4 
 
 
 
 
FIGURE – 8 
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Corneal topography 
 
Two(5%) of the 40 eyes exhibited  an average K- value of <42 D, 31(77.5%) exhibited  
an average K- value of 42.00 D to 47.50 D and seven (17.5%) of the 40 eyes exhibited  
an average K- value of > 47.50D (Table-9, figure -9) 
 
 TABLE 9  - Corneal Topography 
 
 
Corneal 
Topography K Value <42D 
K Value 42.00D to 
47.50D K Value > 47.50D 
No. of eyes 2 31 7 
 
 
 FIGURE – 9 
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Post operative refractive error 
 
At four weeks following surgery, the mean spherical equivalent error was -0.24D (± 
0.12D). The difference between the  preoperative mean spherical equivalent and the post- 
operative mean spherical equivalent values was statistically significant[unpaired ‘t’ test= 
16.673(degree of freedom [d.f.]= 78); 2-tailed P value <0.0001].  
 
Postoperative visual acuity 
 
a) At the first post operative visit, the visual acuity was 6/36 in one(2.5%) of the 40 eyes,  
6/24 in  one(2.5%), 6/18 in two (5%) and 6/12 in two (5%) of the 40 eyes,  6/9p in 
nine(22.5%) and  6/9 in three(7.5%) of the 40 eyes, 6/6p in nine(22.5%) and 6/6 in 
13(32.5%) of the 40 eyes. (Table- 10, Figure- 10).  
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Preoperatively, 14(35%) of 40 eyes had a visual acuity of 6/6p or 6/6 while 
postoperatively( 1st visit) , 22(55%) of 40 eyes had a visual acuity of 6/6p or 6/6; this 
difference was not statistically significant [chi-square with Yate’s correction=-2.475  
(d.f..=1); P= 0.1157].  
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 10 - Postoperative visual acuity first visit 
 
 
Postoperative 
visual acuity 
first visit 
6/36 6/24 6/18 6/12 6/9p 6/9 6/6p 6/6 
No. of eyes 1 1 2 11 9 3 9 13 
 
 
 
 
 
FIGURE – 10 
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 b) At the second postoperative visit, the visual acuity was 1/60 in one(2.5%) of the 40 
eyes, 6/24 in one(2.5%) and 6/12 in two (5%) of the 40 eyes, 6/9p in six(15%) and  6/9 in 
five(12.5%) of the 40 eyes, 6/6p in ten(25%) and 6/6 in fifteen(37.5%) of the 40 eyes  
(Table- 11, figure- 11). 
 
Preoperatively, 14(35%) of 40 eyes had visual acuity of 6/6p or 6/6 while 
postoperatively( 2nd visit) , 25(62.5%) of 40 eyes had a visual acuity of 6/6p or 6/6; this 
difference was stastistically significant [Chi-square with Yate’s correction= 5.003 (d.f.= 
1); P= 0.0253].  
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TABLE 11 - Postoperative visual acuity second visit 
 
 
Postoperative 
visual acuity 
second visit 
1/60 6/24 6/12p 6/9p 6/9 6/6p 6/6 
No. of eyes 1 1 2 6 5 10 15 
 
FIGURE – 11 
 
 
 
c) At the third postoperative visit, the visual acuity was 1/60 in one (2.5%) of the 40 eyes, 
6/12p in two(5%) of the 40 eyes, 6/9p in seven(17.5%) and  6/9 in three(7.5%) of the 40 
eyes , 6/6p in 12(30%) and 6/6 in 15(37.5%)of the 40 eyes(Table- 12, Figure- 12).  
 
Preoperatively, 14(35%) of 40 eyes had visual acuity of 6/6p or 6/6 while 
postoperatively( 3rd visit) , 27(67.5%) of 40 eyes had a visual acuity of 6/6p or 6/6; this 
difference was stastistically significant [Chi-square with Yate’s correction = 7.205 
(d.f.=1); P= 0.0073] 
TABLE 12  - Postoperative visual acuity third visit 
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Postoperative 
visual acuity 
third visit 
1/60 6/12p 6/9p 6/9 6/6p 6/6 
No. of eyes 1 2 7 3 12 15 
 
FIGURE – 12 
 
 
 
 
 
 
d) The postoperative mean best corrected decimal visual acuity was 0.87(±0.22 ) 
(approximately between 6/9 and 6/6), while the preoperative mean decimal visual acuity 
was 0.73(±0.22);  this difference was  statistically significant (P<0.0001). (Table- 13, 
figure- 13). 
 
TABLE 13  - Change in Mean BCVA 
 
 
 
Pre-operative Mean BCVA Post-operative Mean BCVA 
0.73 0.87 
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FIGURE – 13 
 
 
 
 
 
 
 
 
Gain or loss of vision in the study eyes following implantation of pIOL 
a) Twenty- one (52.5%) of the 40 eyes gained one or more lines of BCVA, 16 (40%) had 
no change in BCVA and three (7.5%) of the 40 eyes actually lost one or more lines of 
visual acuity. (Table- 14, figure- 14).  
 
TABLE 14  - Gain or loss of vision in the study following implantation of pIOL 
 
 
Gained one  or more 
lines of BCVA No change in BCVA  
Lost one or more 
lines of visual 
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acuity 
21 16 3 
 
 
 
FIGURE – 14 
 
 
 
b) Eighteen (45 %) of the 40 eyes had a preoperative refractive error >12D (extreme 
myopia) while 22 (55%) of the 40 eyes had a preoperative refractive error < 12  D. Of the 
18 eyes with a preoperative error > 12 D, 12 gained one or more lines of BCVA, four  
had no change in BCVA and 2  lost one or more lines of visual acuity following surgery  
while of the 22 eyes with preoperative error <  12 D, nine gained one  or more lines of 
BCVA,  12  had no change in BCVA and one eye lost one or more lines of visual acuity 
following surgery (Table- 15, figure- 15) ; this difference approached , but did not 
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achieve statistical significance ( chi-square with Yate’s correction = 4.56 [d.f.=2] ; P= 
0.07).  
TABLE 15 -  Preoperative Refractive Error >12D and <12D 
 
  
Gained one  or 
more lines of 
BCVA 
No change 
in BCVA  
Lost one or more 
lines of visual acuity 
Pre-operative Refractive 
Error >12D  12 4 2 
Pre-operative Refractive 
Error  < 12  D 9 12 1 
 
FIGURE – 15 
 
Efficacy  index  
The efficacy index (ratio of  mean postoperative UCVA to mean  preoperative 
BCVA) was calculated to be 1.18, indicating that the postoperative mean uncorrected 
visual acuity was better than the preoperative mean best corrected visual acuity.  
 
Safety index  
The safety index (ratio of mean postoperative BCVA to mean  preoperative 
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BCVA) was calculated to be 1.23; indicating that the  postoperative mean best corrected 
visual acuity was better than the preoperative mean best corrected visual acuity.  
 
Predictability  
This was calculated to be 100% 
 
Complications 
a) Five (12.5%) of the 40 eyes had a transient rise in intraocular pressure (IOP), which 
was controlled by topical medication.  
 
b) Only one patient developed a severe rise in IOP, in one of the two eyes operated; in 
view of the intractable glaucoma, the ICL had to be replaced. In this patient, the 
preoperative spherical equivalent (SE) was 21D and post operative visual acuity was 
1/60.  
 
c) No other complications were observed during the study. 
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DISCUSSION  
 
Myopia is a common cause of visual disability throughout the world. The World 
Health Organization has grouped myopia and uncorrected refractive error among the 
leading causes of blindness and vision impairment in the world 
(http://www.who.int/blind-ness/causes/priority/en/index5.html, accessed 1st December 
2010).  Recent studies have confirmed the existence of a large burden of uncorrected 
refractive errors, although the interventions required are significantly cost effective, and 
have an important impact on economic development and quality of life. Severe refractive 
errors have been estimated to account for about 5 million blind people 
(http://www.who.int/blind-ness/causes/priority/en/index5.html; accessed 1st December 
2010). Hence, any study on modalities of correction (treatment) of these priority eye 
diseases is of great relevance.   
 
There are two main types of surgical correction for moderate to high myopia, 
namely, excimer laser and phakic intraocular lenses (pIOLs). Basically, in excimer laser 
refractive surgery for myopia, some portion of the corneal stroma is removed to reduce 
the refractive power of the cornea and therein to bring the image of a viewed object into 
focus onto the retina rather than in front of it. Conversely, pIOLs used for the treatment 
of myopia work by diverging light rays so that the image of a viewed object is brought 
into focus onto the retina rather than in front of it.  
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Surgical correction of astigmatism by IOL implantation has advanced rapidly in the past 
few years. Toric IOL implantation is a reversible procedure that can correct astigmatism 
and spherical refractive errors while preserving the corneal contour. The use of pIOLs is 
a small but emerging area in refractive surgery. For patients with high myopia and 
inadequate vision with glasses or intolerance to contact lenses, options are limited. 
Corneal refractive surgery such as laser in-situ keratomileusis (LASIK) can safely and 
reliably correct myopia up to approximately – 12 D, but at higher diopters,  it achieves 
less satisfactory results along with increased risks of corneal ectasia. In addition, IOL 
implantation with lensectomy yields loss of accommodation, along with increased risks 
of retinal detachment in high myopes. The advent of pIOLs offers the possibility of 
refractive correction without the loss of accommodation. 
 
 
Fyodorov developed the first posterior chamber pIOL in 1986. Interestingly, 
Bozkurt et al.(2010) have recently  described a patient who had received such a pIOL 
(Fyodorov IOL) 18 years previously to correct myopia; after a long lapse in the follow-
up, the patient presented with a reduced endothelial cell count but without any sign of 
cataract9. The patient was totally satisfied even after 18 years. Borzkut et al. (2010) 
believed that theirs was the first report of a long follow-up of a patient implanted with a 
first-generation PC pIOL. 
 
Posterior chamber pIOLs came to the market as the Chiron-Adatomed Lens 
(Chiron- Adatomed GmbH, Munich, Germany), and the Visian Implantable Collamer 
Lens (Staar  
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Surgical, Monrovia, CA). The most recent design of the Visian lens (V4 ICL) was approved 
By the United States (US) Food and Drug Administration (FDA) in December 2005. It is 
made of collamer, ahydrophilic porcine collagen/hydroxyethyl methacrylate(HEMA) 
copolymer, with an ultraviolet-absorbing chromophore. The Visian ICL features a plate 
haptic design with central convex/concave optical zone and incorporates a forward vault  
to minimize contact of ICL with the capsule of the normal crystalline lens .This ICL 
features an optic diameter with an overall diameter that varies with the dioptric power, 
the smallest optic/overall diameter being 4.9mm/12.1mm and largest optic/overall 
diameter being  5.8mm/13.7mm . The lenses are capable of being folded and inserted into 
the posterior chamber (behind the iris and in front of anterior capsule of cryastalline lens)  
through an incision of 3.5mm or less. The lens functions as a refractive element to 
optically reduce moderate to high myopia  The Staar ICL for myopia correction is the 
first phakic IOL approved in the US by FDA in 2004. It is the first IOL of any kind to be 
approved for patients younger than 60 yrs and  a refractive procedure correcting myopia  
ranging from -3D to ≤15D and with astigmatism ≤ 2.5D. It also reduces myopia ranging 
from  greater than -15D  to -20D 
 
 
Another commercially available posterior chamber pIOL (not yet FDA approved) 
is the Phakic Refractive Lens or PRL (Ciba Vision, Duluth,GA,USA; Medennium Inc., 
Irvine,  CA, USA), which is made of hydrophilic silicone. 
 
Barsam and Allan (2010) reviewed  the effects of excimer laser refractive surgery 
versus phakic IOLs for the correction of moderate to high myopia10. They  searched the 
Cochrane Central Register of Controlled Trials (CENTRAL), as well as MEDLINE, 
 55
EMBASE and Latin American and Caribbean Literature on Health Sciences (LILACS); 
randomised controlled trials (RCTs) comparing excimer laser refractive surgery and 
phakic IOLs for the correction of myopia greater than 6.0 D spherical equivalent were 
included. The  review included three RCTs with a total of 228 eyes. The range of myopia 
in the patients included  was -6.0 D to -20.0 D of myopia with up to 4.0 D of myopic 
astigmatism. The percentage of eyes with uncorrected visual acuity (UCVA) of 20/20 or 
better at 12 months postoperative was not significantly different between the two groups. 
Phakic IOL surgery was deemed to be safer than excimer laser surgical correction for 
moderate to high myopia as it resulted in significantly lower loss of best spectacle 
corrected visual acuity (BSCVA) at 12 months postoperatively. However, there was a 
low risk of developing early cataract with phakic IOLs. Phakic IOL surgery appeared to 
result in better contrast sensitivity than excimer laser correction for moderate to high 
myopia. Phakic IOL surgery also scored more highly on patient satisfaction/preference 
questionnaires. The authors concluded that the results of their review  suggested that  
pIOLs are safer than excimer laser surgical correction for moderate to high myopia in the 
range of -6.0 to -20.0 D , and that pIOLs are preferred by patients. However, these 
authors were also of the opinion that while pIOLs might be accepted in clinical practice 
for higher levels of myopia (greater than or equal to 7.0 D of myopic spherical equivalent 
with or without astigmatism), it might also be worth considering pIOL treatment over 
excimer laser correction for more moderate levels of myopia (less than or equal to 7.0 D 
of myopic spherical equivalent with or without astigmatism). There have been similar 
studies in the past where ICL implantation was considered in eyes with both moderate to 
high as well as low myopia (Zaldivar R et al .1998; Sanders DR et al 1998; Jime´nez-
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Alfaro I et al 2001 etc). 11-20 .Sanders and Vukich reported that ICL had advantages over 
Lasik , not only in eyes with moderate to high myopia but also with low myopia21-23 
In view of the observations made by Barsam and Allan in their review, it is surprising 
that there are just a handful of  documented investigations in the literature pertaining to 
studies done in India. A search of the Pub Med database using the key words `phakic 
intraocular lenses; studies in India’  generated just four  papers (Titiyal et al. 2010; 
Senthil et al. 2006; Bhattacharjee et al. 2006; Fechner et al. 1998). 24-27   Of these, only  
one  paper (Senthil et al. 2006) is relevant to the subject of the present dissertation, 
posterior  chamber pIOLs; moreover, that study dealt with Artisan pIOLs.  Hence, the 
investigation  on which this present dissertation is based appears to be unique in a  
number of respects.  
 
 
The purpose of this study, conducted in a tertiary eye care hospital in southern 
India, was to assess the visual outcomes, safety, efficacy and predictability of ICL 
implantation for correction of moderate to high myopia.  
 
In the present study, there were 25 patients (sixteen females and nine males;  
mean age of  24.04 ±5.5 years). Forty eyes of these 25 patients presented with the 
spherical equivalent (SE) between -5.50 and -21.0 dioptres (D) and only one eye with SE 
< 5.0D. There were eight eyes with simple myopia (20%) and 32 eyes with compound 
myopic astigmatism (80%) The right eye was involved in seven of the eight eyes with 
simple myopia and only a single left eye had simple myopia. Implantable collamer lens 
(ICL) lens was inserted in myopic eyes; there were 10 patients with ICL implanted in one 
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eye and 15 patients with ICL implanted in both the eyes. Post-operative follow-up 
occurred at one, two and four  weeks.  
 
 
  In the present study, the mean decimal visual acuity preoperatively was 0.73(± 
0.22) (approximately between 6/9 and 6/6) and the postoperative mean best corrected 
decimal visual acuity was 0.87(±0.22 ) (approximately between 6/9 and 6/6); this 
difference was  highly statistically significant.  
 
Twenty-one (52.5%) of the 40 eyes gained one or more lines of BCVA. 
Comparison of post-operative visual results in which patients with preoperative myopia  
< 12D and those with preoperative myopia >12D (extreme myopia) revealed that 12 
(67%) of 18 eyes in the extreme myopia group gained one or more lines of BCVA as 
compared to nine (41 %) of 22 eyes in patients with myopia < 12 D. Although the 
difference appears sizable, in statistical terms, the difference only approached statistical 
significance (P= 0.07) without achieving it. However, it  should be noted that gain in one 
or more lines and improvement in visual acuity in patients with extreme myopia is 
significant because the minification effect of glasses is reduced as the ICL implantation 
moves the focus close to the nodal point of the eye, leading to visual improvement;  in 
comparison, in patients with < 12D, vision remains stable and may not achieve 
significant improvements as in patients with  extreme myopia.  
 
 
Alonso et al. (2010a) assessed the predictability, efficacy, safety, and stability of a 
collagen copolymer toric pIOL (Intraocular Collamer Lens) implantation to correct 
moderate to high myopic astigmatism in an ophthalmological institute in Spain.28 The 
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uncorrected and corrected distance visual acuities, refraction, pIOL vault, and adverse 
events were evaluated over 12 months. Preoperatively, the mean sphere in the 55 eyes 
was _4.65  D (standard deviation [SD] 3.02) (range _0.50 to _12.50 D) and the mean 
cylinder, _3.03 (SD 0.79)  D (range _1.25 to _4.00 D).At 12 months, the mean Snellen 
decimal UCVA was 0.80 (SD 0.20) and the mean BCVA was 0.85 (SD0.18); 62.0% of 
eyes had a BCVA of 20/20. More than 50.0% of eyes gained one or more lines of BCVA. 
The treatment was highly predictable for spherical equivalent  and astigmatic. Of the 
eyes, 94.5% were within 0.50 D of the attempted SE and all were within 1.00 D. The 
efficacy index was 0.95 at 3 months and 1.08 at 1 year. The authors concluded that the 
UCVA and BCVA with toric pIOLs were good and highly stable over 12 months, 
confirming that the procedure was safe, predictable, and effective for correction of 
moderate to high astigmatism. When comparing the results of the present investigation 
with those reported  by Alonso et al. (2010 a), it is interesting to note that in the present 
investigation, 52.5 % of patients gained more than one line of BCVA and the safety index 
and efficacy index were both more than 1, while  in  the study by Alonso et al. (2010 a), 
more than 50.0% of eyes gained one or more lines of BCVA, and the efficacy index was 
less than 1 at 3 months and only exceeded 1 after 12 months.  
 
 
In another recent study, Alfonso and co-investigators (2010b) assessed the safety, 
efficacy, stability, and predictability after implantation of a toric intraocular copolymer 
(Collamer) lens (pIOL) to correct high myopic astigmatism in 15 eyes of 12 patients (9 
women) in an ophthalmological institute in Spain.29 Preoperatively, the mean manifest 
spherical refraction was -1.98 D (SD 1.32) (range -0.50 to -5.50 D) and the mean 
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refractive cylinder was  -4.85 (SD 0.83)  D (range -6.50 to -4.00 D). At 12 months, the 
mean refractive cylinder was -0.55 (SD 0.52)  D (range -1.50 to 0.00 D), with 93.3% of 
eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -0.31 (SD 
0.42) (range -1.00 to 0.75 D), with more than 70% of eyes within 0.50 D of the target. 
For the astigmatic components, 93.3% of eyes were within 1.00 D of J0  and all eyes 
were within 1.00 D of J45. The mean UCVA was 0.70 (SD 0.20) and the mean BCVA 
was 0.83 (SD 0.12). The overall efficacy index was 0.90. Postoperatively, all eyes had 
unchanged UCVA or gained one or more lines. The authors concluded that  refractive 
outcomes and improvement in UCVA and BCVA were rapidly achieved and remained 
fairly consistent throughout the follow-up period, supporting the use of toric pIOLs in 
eyes with high astigmatism. 
 
 
Several adverse events have been reported to occur with the use of posterior 
chamber pIOLs; these range from mild corneal oedema and iritis to more severe 
complications such as  clinically significant endothelial cell loss, pigment dispersion 
syndrome, pigmentary glaucoma and pupillary block ,significant  cataract, glaucoma,  
macular/subretinal  haemorrhage and retinal detachment (Guell et al. 2010).30  
 
 
 
However, in the present study, few adverse events were noted. Five (12.5%) of 
the 40 eyes exhibited a transient rise in IOP which was controlled by topical medication. 
Only one patient developed a marked rise in IOP in one of the two eyes operated; this 
patient with intractable glaucoma required replacement of ICL, his preoperative spherical 
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equivalent (SE) was 21D and post operative visual acuity was 1/60. No other 
complications were observed during the course of this study. 
                                                                                                                    
 
 
Yousef et al. (2010) in the USA assessed the histopathology of anterior 
subcapsular cataract associated with the use of the Visian ICL using light microscopy 
after pIOL explantation and cataract surgery.31 Pathology specimens related to explanted 
pIOLs were reviewed and preoperative and postoperative patient data collected. The 
anterior lens capsules and explanted pIOLs were examined. Four eyes (three  patients) 
had pIOL explantation for low vault and anterior subcapsular cataract. The explanted 
pIOLs were the shorter length models (3, 12.1 mm; 1, 12.6 mm). Anterior segment 
optical coherence tomography (AS-OCT) confirmed the low pIOL vault before 
explantation in 2 eyes. Histopathology of the anterior subcapsular cataract showed 
fibrous metaplasia with a variable number of lens epithelial cell (LEC) layers attached to 
the inner surface of the anterior capsulorhexis specimens. Light microscopy of the 
explanted pIOLs showed no pigment on 1 lens, mild pigment deposition on 1 haptic, and 
pigment deposition throughout the anterior surface of 2 pIOLs.. The authors concluded 
that anterior subcapsular cataract associated with the pIOLs was caused by low vaulting 
(confirmed on AS-OCT) and consequent fibrous metaplasia of the anterior LECs.  
 
 
In the present study, none of the eyes appeared to have developed a cataract. 
However, the short follow-up period of the present investigation may account for the 
absence of such a finding. USFDA Clinical trial of ICL in moderate to high myopia  
showed complications (between 1 and 36 months) occurring in ≤ 1% of cases and 
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included  retinal detachments in 0.6%, glaucoma in 0.4%, clinically significant surgically 
induced anterior subcapsular cataract in 0.4% and macular/subretinal haemorrhage in 
0.2%  cases. There were no cases of persistent corneal oedema, hypopyon, hyphema 
macular oedema and endophthalmitis 
 
 
          The clinical trials involved in the FDA approval process for the Visian ICL showed 
it could provide a safe, reversible method of correcting moderate to high myopia which is 
similar to this study. However, one of the risks associated with posterior chamber PIOLs, 
but less so with anterior chamber PIOLs, is the development  of cataracts. There was no 
incidence of lens opacification observed in this study.   
 
Sanders’ 2007 report examined the development of cataracts 5 years after surgery 
in the Visian Lens FDA trial. Their study enrolled 291 patients (526 eyes) with myopia 
ranging between – 3 and – 20.0 D. At 12 months postoperatively, UCVA was 20/40 or 
better in 92.5% and 20/20 or better in 60.1%. The most common adverse event was 
anterior subcapsular opacities.Sanders’ most recent study reported the development of 
anterior subcapsular opacities during a minimum 5-year follow-up period. He found that 
anterior subcapsular opacities occurred in 5.9% of eyes at 7+ years. They generally 
occurred early, with 58% being seen in the first year, 68%in the first 2 years, and 74%in 
the fist 3 years. However, only 1.3% progressed to clinically significant cataract, and 
those were usually in very high myopes and older patients. 
 
A recent meta analysis by Chen et al in 2008 involved a systemic literature review 
to determine the incidence of and predisposing factor for cataract after PIOL implantation 
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 Of 6338 eyes, 4.35% were noted to have new-onset or preexisting progressive cataract. 
 
  The study included angle supported, iris-supported, and posterior chamber PIOLs. 
The incidence of cataract formation was 1.29%, 1.11%, and 9.60%, respectively. 
Amongst the new-onset cataracts, nuclear sclerosing was the predominant type in the 
anterior chamber  group (60.0%) and iris-fixed group (50.0%), whereas anterior 
subcapsular was the predominant type in the posterior chamber group (90.58%). These 
results suggest that cataract formation is most likely to occur after posterior chamber 
PIOL implantation. In the posterior chamber PIOL group, early cataract formation was 
related to surgical trauma and late cataract formation was related to IOL-crystalline lens 
contact. 
 
A limitation of the present investigation is that the duration of the study was 
relatively  short (one year); a longer follow up  is needed to assess final visual outcome 
and safety  of the procedure in the population of patients from which the study patients 
were chosen.  
 
Another limitation of this study is that endothelial cell counts were not measured. 
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     CONCLUSION  
 
The present study was undertaken to assess the efficacy of the implantable 
collamer lens (ICL) in correction of myopia (including moderate to high myopia) in a 
southern Indian population, an aspect on which there appears to be limited verifiable 
data. The results of the present study suggest that phakic intraocular lens implantation for 
the correction of myopia seems to be an effective and predictable procedure for moderate 
to high myopia. However, a longer follow up is required to assess the effect of age- 
related changes, such as an increase in the thickness of the lens. 
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 SUMMARY 
 
 
Myopia and uncorrected refractive error are among the leading causes of 
blindness and vision impairment in the world, hence studies on modalities to correct these 
priority eye diseases are of great relevance. There are two main types of surgical 
correction for moderate to high myopia, namely excimer laser and phakic intraocular 
lenses (pIOLs)..  The use of pIOLs is a small but emerging area in refractive surgery. A 
recent evidence-based review suggested that phakic IOLs are safer than excimer laser 
surgical correction for moderate to high myopia in the range of -6.0 to -20.0 D,  and that 
pIOLs are preferred by patients. However, there are just a handful of documented 
investigations in the literature pertaining to studies on pIOLs done in India. The present 
investigation is believed to be the first in southern India to investigate the efficacy of the 
implantable collamer lens (ICL) for the correction of myopia.  
 
Twenty five patients were enrolled in this study , of whom 16 (64%) were females 
and nine  (36%) were males.  The mean age of the patients was 24.04 (±5.5) years. There 
were 10 patients with an ICL implanted in one eye and 15 patients with ICLs implanted 
in both eyes, that is, a total of 25 patients and 40 eyes[right eye 20(50%);left eye 
20(50%)] were evaluated in the study.  
 
In the 40 eyes, the mean spherical equivalent prior to surgery was -12.15 D (± 
4.52 D). Eight (20%) of the 40 eyes presented with simple myopia while 32 (80%) of the 
40 eyes presented with compound myopic astigmatism (80%). In the 40 eyes, the 
preoperative mean decimal visual acuity was 0.73(± 0.22) (approximately between 6/9 
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and 6/6). The mean preoperative central corneal thickness was 511.6(± 36.8)µ and the 
mean preoperative anterior chamber depth was 3.43(± 0.36) mm. Two(5%) of the 40 eyes 
exhibited  an average K- value of <42 D, 31(77.5%) exhibited  an average K- value of 
42.00 D to 47.50 D and seven (17.5%) of the 40 eyes exhibited  an average K- value of > 
47.50D.   
 
At four weeks following surgery, the mean spherical equivalent error was -0.24D 
(± 0.12D). The difference between the  preoperative mean spherical equivalent and the 
post- operative mean spherical equivalent values was statistically significant [P <0.0001].  
 
Preoperatively, 14(35%) of 40 eyes had a visual acuity of 6/6p or 6/6. At the first 
post- operative visit, 22(55%) of 40 eyes had a visual acuity of 6/6p or 6/6, at the second 
post-operative visit 25(62.5%) of 40 eyes had a visual acuity of 6/6p or 6/6 while at the 
third visit, 27(67.5%) of 40 eyes had a visual acuity of 6/6p or 6/6. The difference 
between the proportion of eyes with visual acuity of  6/6p or 6/6  pre-operatively and  
that at the first post-operative visit was not stastistically significant. However, the 
difference between the proportion of eyes with visual acuity of  6/6p or 6/6 pre-
operatively and that at the second post-operative visit was stastistically significant 
(P=0.0253).  Similarly, the difference between the proportion of eyes with visual acuity 
of  6/6p or 6/6  pre-operatively and that at the third post-operative visit was stastistically 
significant (P= 0.0073).  
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The postoperative mean best corrected decimal visual acuity was 0.87(±0.22 ) 
(approximately between 6/9 and 6/6), while the preoperative mean decimal visual acuity 
was 0.73(±0.22);  this difference was  statistically significant (P<0.0001). 
 
Twenty- one (52.5%) of the 40 eyes gained one or more lines of best corrected 
visual acuity (BCVA), 16 (40%) had no change in BCVA and three (7.5%) of the 40 eyes 
actually lost one or more lines of visual acuity.  
 
Eighteen (45 %) of the 40 eyes had a preoperative refractive error >12 D (extreme 
myopia) while 22 (55%) of the 40 eyes had a preoperative refractive error  < 12  D. Of 
the 18 eyes with a preoperative error > 12 D, 12 gained one  or more lines of BCVA, four  
had no change in BCVA and two lost one or more lines of visual acuity following surgery  
while of the 22 eyes with preoperative error <  12 D, nine gained one  or more lines of 
BCVA,  12  had no change in BCVA and one eye lost one or more lines of visual acuity 
following surgery; this difference approached but did not achieve, statistical 
significance(P= 0.07)   
 
The efficacy index (ratio of  mean postoperative UCVA to mean  preoperative 
BCVA) was calculated to be 1.18, indicating that the postoperative mean uncorrected 
visual acuity was better than the preoperative mean best corrected visual acuity.  
 
The safety index (ratio of mean postoperative BCVA to mean  preoperative 
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BCVA) was calculated to be 1.23; indicating that the  postoperative mean best corrected 
visual acuity was better than the preoperative mean best corrected visual acuity.  
 
The predictability was calculated to be 100% 
 
With regard to complications, five (12.5%) of the 40 eyes had a transient rise in 
intraocular pressure (IOP), which was controlled by topical medication. Only one patient 
developed a severe rise in IOP,  in one of the two eyes operated; in view of the intractable 
glaucoma, the ICL had to be replaced. In this patient, the preoperative spherical 
equivalent (SE) was 21 D and post operative visual acuity was 1/60. No other 
complications were observed during the study. 
 
A limitation of the present study is that the duration was relatively short (one 
year); a longer follow- up  is necessary to assess final visual outcome and safety of the 
procedure. An additional limitation of this study is that endothelial cell counts were not 
measured 
 
The results of the present study suggest that phakic intraocular lens implantation 
for the correction of myopia seems to be an effective and predictable procedure for 
patients who present with moderate to high myopia.  However, a longer follow up is 
required to assess the effect of age-related changes, such as an increase in the thickness of 
the lens.  
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                                                            PROFORMA  
 
M.R.NO:                                                                                                                DATE:  
AGE/SEX: 
HISTORY: 
OCCUPATION: 
COMPLAINTS: 
OCULAR EXAMINATION: 
                                                                     RE                                                  LE 
VISUAL ACUITY: 
 DISTANCE:  
 NEAR: 
 BEST CORRECTED VISUAL ACUITY: 
 SLIT LAMP EXAMINANTION 
FUNDUS EXAMINATION: 
DIAGNOSIS:   
INTRAOCULAR PRESSURE 
CORNEAL TOPOGRAPHY: 
ANTERIOR CHAMBER DEPTH: 
CENTRAL CORNEAL THICKNESS: 
WHITE- WHITE DIAMETER: 
POSTOPERATIVE VISUAL ACUITY: 
COMPLICATIONS: 
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AFTER 
1 WEEK
AFTER 
2 WEKS
AFTER 4 
WEEKS
1 721875 18 F LE 1/60. RE-14.50/-1.75×17015.37 6/9.
Disc partially 
tilted
Compound 
Myopic 
Astigmatism 538 45.87-76 44.00-166 3.85 11.75 6/6p 6/6P. 6/6P. NIL 9 months
2 707494 22 M RE 5/60. RE -9.75 Dsph 9.75 6/6. Normal
Simple 
Myopia 479 41.87-180 41.87-90 3.41 11.25 6/6. 6/6. 6/6. NIL 1 year
3 628481 22 F LE 3/60. LE -11.75/-1.25×16012.37 6/12p
Peripapillary 
Atrophy
Compound 
Myopic 
Astigmatism 547 49.00-76 47.12-166 3.77 11 6/6p 6/6P. 6/6P. NIL
9 months 
3 weeks
4 710904 19 F LE 6/60. LE -5.00/-1.00×70 5.5 6/6. Normal
Compound 
Myopic 
Astigmatism 481 45.37-152 44.87-62 3.3 11.5 6/6P. 6/6. 6/6. NIL 4 weeks
5 733184 28 M RE 3/60. RE -14.00/-1.00×40 14.5 6/9.
Myopic 
fundus
Compound 
Myopic 
Astigmatism 573 44.75-144 43.62-54 4.26 12 6/6. 6/6. 6/6. NIL 3 months
6 740026 22 F LE 5/60. LE -9.00/-0.50×170 9.25 6/9.
Temporal 
crescent
Compound 
Myopic 
Astigmatism 503 43.62-80 42.87-170 3.3 11 6/6P. 6/6P. 6/6P. NIL 5 weeks
7 678160 28 M LE 6/60. LE -4.50/-2.25×155 5.62 6/12p Normal
Compound 
Myopic 
Astigmatism , 428 54.5-68 51.75-158 3.8 11.25 6/24. 6/12P 6/9P. NIL
2 month 1 
week
8 760820 38 F RE 3/60. RE-15 Dsph 15 6/6.
Tilted disc 
with Temporal 
crescent
Simple 
Myopia 553 43.25-110 42.62-20 3.29 12 6/6. 6/6. 6/6., NIL 1 month
9 740378 28 M RE 5/60. RE -11.00/-1.00×10 11.5 6/12p Normal
Compound 
Myopic 
Astigmatism 562 46.62-94 44.00-4 3.73 11 6/9P 6/12P 6/12P NIL 4 months
10 637148 22 M RE 3/60. RE-5.25/-2.00×20 6.25 6/12p
Temporal 
crescent
Compound 
myopic 
astigmatism 419 41.37-114 39.12-24 2.81 10.5 6/9p 6/9p 6/9P. NIL
1 month 2 
weeks
C
O
R
N
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L 
TO
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G
R
A
PH
Y 
(D
)
11 722715 18 F RE 2/60. RE-18.00 18 6/12. Normal
Compound 
Myopic 
Astigmatism 512 45.62-180 45-90 2.92 11 6/6. 6/6. 6/6. NIL 1 month
LE 2/60. LE -19.00/-0.25×14519.12 6/12. Normal
Compound 
Myopic 
Astigmatism 512 45.62-180 45-90 3.42 11 6/9p 6/9P. 6/9P. NIL 5 months
12 699966 39 M RE 3/60. RE-17.00/-1.00×10 17.5 6/9.
Posterior 
staphyloma
Compound 
Myopic 
Astigmatism 549 44.12-110 43.62-20 3.4 11.25 6/9P. 6/6P. 6/6P. NIL 11 months
LE 3/60. LE -16.75/-0.75×16017.12 6/9.
Posterior 
staphyloma
Compound 
Myopic 
Astigmatism 554 46.62-78 44.12-168 3.39 11.25 6/9P. 6/6P. 6/6P. NIL 11 months
13 696919 22 F RE 3/60. RE-5.50/-0.50×180 5.75 6/6. Normal
Compound 
myopic 
astigmatism 506 48.50-88 47.12-178 3.31 11.5 6/6. 6/6. 6/6. NIL 5 weeks
LE 3/60. LE-5.50/-0.50×160 5.75 6/6. Normal
Compound 
myopic 
astigmatism 509 48.50-96 47.50-6 3.45 11.5 6/6. 6/6. 6/6. NIL 5 weeks
14 703424 28 F RE 5/60. RE -14.00/-2.00×18015 6/6. Normal
Compound 
myopic 
astigmatism 476 48.37-108 46.12-18 3.08 12 6/6. 6/6. 6/6. NIL 5 weeks
LE 5/60. LE -14.00/-2.00×18015 6/6. Normal
Compound 
Myopic 
Astigmatism 477 48.12-112 46.5-22 3.56 12 6/9P. 6/9. 6/9. NIL 4 weeks
15 704012 25 M RE 3/60. RE-10.00/-2.00×18011 6/6. Normal
Compound 
Myopic 
Astigmatism 477 48.87-98 46.89-8 3.08 11 6/18. 6/9p 6/9P. NIL 1 month
LE 3/60. LE-13.00/-2.00×180 14 6/9. Normal
Compound 
Myopic 
Astigmatism 476 49.25-98 46.87-4 3.1 11.5 6/18. 6/9p 6/9P. NIL 1 month
16 718347 24 F RE 2/60. RE -12.00 Dsph 12 6/9. Normal
Simple 
Myopia 517 45.00-90 44.87-180 3.72 11 6/6p 6/6P. 6/6P. NIL 6 weeks
LE 2/60. LE-10.00/-1.00×180 10.5 6/9. Normal
Compound 
Myopic 
Astigmatism 519 45.00-90 44.87-180 3.73 11 6/6p 6/6P. 6/6P. NIL 6 weeks
17 746556 20 F RE 6/60. RE-11.00/-1.50×5 11.75 6/9. Normal
Compound 
Myopic 
Astigmatism 544 46.87-112 44.75-22 3.21 11 6/6p 6/6p 6/6p NIL 5 months
LE 4/60. LE -10.00/-2.00×17511 6/9. Normal
Compound 
Myopic 
Astigmatism 551 47.37-94 44.62-4 3.71 11 6/6P 6/9. 6/9. NIL 5 months
18 748407 21 F RE 2/60. RE -19.50/-1.25×17020.75 6/12p
Peripapillary 
Atrophy
Compound 
Myopic 
Astigmatism 523 45.00-100 43.75-10 2.98 12 6/9p 6/9P 6/9P. NIL 3 months
LE 2/60. LE -19.75/-1.50×15 20.5 6/12.
Peripapillary 
Atrophy
Compound 
Myopic 
Astigmatism 523 44.87-100 43.12-10 2.98 12 6/12. 6/9p 6/9P. NIL 3 months
19 723556 19 M RE 2/60. RE -10.50 Dsph 10.5 6/6p
Lattice 
degeneration
Simple 
Myopia 577 43.12-90 42.87-180 4.04 12 6/6. 6/6. 6/6. NIL 9 months
LE 2/60. LE-9.75/-0.75×180 10.12 6/6p
Lattice 
degeneration
Compound 
Myopic 
Astigmatism 563 43.25-94 42.87-180 4.04 12 6/6. 6/6. 6/6. NIL 9 months
20 722708 22 F RE 5/60. RE-7.25/-0.75×30 7.62 6/6p Normal
Compound 
Myopic 
Astigmatism 462 44.87-108 43.75-18 3.66 12 6/6. 6/6. 6/6. NIL
7 months 
1 week
LE 5/60. LE-6.75/-1.00×170 7.25 6/6p Normal
Compound 
Myopic 
Astigmatism 464 45.37-84 44.00-174 4.21 12 6/6P. 6/6. 6/6. NIL
7 months 
1 week
21 701209 RE 5/60. RE -8.00 Dsph 8 6/9. Normal
Simple 
Myopia 499 47.87-118 47.00-168 3.14 11.75 6/9P. 6/6P. 6/6P. NIL 1 month
LE 5/60. LE -9.00 Dsph 9 6/9. Normal
Simple 
Myopia 499 47.00-28 46.00-78 3.56 11.75 6/9P. 6/6P. 6/6P. NIL 1 month
22 731642 19 M RE 1/60. RE-20Dsph/-2.00×18021 6/24.
Peripapillary 
Atrophy
Compound 
Myopic 
Astigmatism 529 47.50-96 44.87-6 3.11 11 6/36. HM 1/60. GLAUCOMA4 months
LE 1/60. LE-18.75Dsph/-2.00×18019 6/12p
Peripapillary 
Atrophy
Compound 
Myopic 
Astigmatism 531 46.75-80 45.00-170 3.079 11 6/12. 6/24. 6/12p NIL 4 months
23 761071 22 F RE 2/60. RE-13 Dsph 13 6/9p
Lattice 
degeneration
Simple 
Myopia 509 46.25-90 47.00-74 2.98 11.25 6/9. 6/9. 6/6P. NIL 2 months
LE 5/60. LE -9.00/-1.00×150 10 6/9p
Lattice 
degeneration
Compound 
Myopic 
Astigmatism 507 46.00-180 45.62-164 2.97 11.25 6/9. 6/9. 6/6P. NIL 2 months
24 760482 24 F RE 5/60. RE-12.25/0.50×25 12.5 6/12.
Lattice 
degeneration
Compound 
myopic 
astigmatism 520 45.37-106 45.37-90 3.52 11.5 6/9. 6/9. 6/9. NIL 1 month
LE 5/60. LE-9.00/-1.25×180 12.87 6/9.
Lattice 
degeneration
Compound 
myopic 
astigmatism 516 44.50-16 44.62-180 3.52 11.5 6/6. 6/6. 6/6., NIL 1 month
25 750534 27 F RE 6/60. RE-7.50 Dsph 7.5 6/6. Normal
Simple 
Myopia 495 46.75-80 48.37-98 3.3 11 6/6. 6/6. 6/6. NIL 1 month
LE 6/60. LE -7.50/-1.00×180 8 6/6. Normal
Compound 
Myopic 
Astigmatism 482 46.12-170 46.87-8 3.33 11 6/6. 6/6. 6/6. NIL 1 month
